Table 2.
Baseline demographic and clinical characteristics of patient by age
| ≤64 years (N = 47) | ≥ 65 years (N = 42) | p-value | |||
|---|---|---|---|---|---|
| Mean/ Median/ Number | SD/IQR/(%) | Mean/ Median/ Number | SD/IQR/(%) | ||
| Age | 60.5 | 55.8–63.3 | 68.1 | 66.8–68.8 | < 0.001 |
| Sex | 16 | 38.1 | 21 | 44.7 | 0.535 |
| BMI (Kg/m2) | 29.3 | 3.8 | 29.4 | 4.6 | 0.924 |
| Office systolic blood pressure (mmHg) | 131.6 | 16.5 | 133.5 | 16.4 | 0.575 |
| Office diastolic blood pressure (mmHg) | 81.0 | 9.2 | 80.0 | 9.0 | 0.608 |
| Pulse pressure (mmHg) | 52.0 | 40.9–56.3 | 51.0 | 41.5–64.5 | 0.326 |
| Heart rate (beats/min) | 73.1 | 11.2 | 71.6 | 12.4 | 0.567 |
| Smoker n (%) | 4 | 9.5 | 3 | 6.4 | 0.542 |
| Physical activity (METS-min/week) | 1689.3 | 779.8–2772.0 | 1406.0 | 757.0–2972.0 | 0.745 |
| Intensity of the walk | 0.940 | ||||
| - Low | 20 | 47.6 | 22 | 46.8 | |
| - High | 22 | 52.4 | 25 | 53.2 | |
| Hypertensive n (%) | 23 | 54.8 | 24 | 51.1 | 0.731 |
| Dyslipemic n (%) | 25 | 59.5 | 28 | 59.6 | 0.996 |
| HbA1c % | 6.6 | 6.0–7.3 | 6.6 | 6.0–7.4 | 0.725 |
| Serum glucose (mg/dl) | 116.0 | 98.8–140.5 | 122.0 | 100.0–138.0 | 0.977 |
| Total Cholesterol (mg/dl) | 180.7 | 29.5 | 178.8 | 26.7 | 0.753 |
| Triglycerides (mg/dl) | 106.0 | 74.0–128.0 | 112.0 | 83.0–149.0 | 0.357 |
| HDL Cholesterol (mg/dl) | 53.9 | 12.2 | 56.0 | 15.8 | 0.505 |
| LDL Cholesterol (mg/dl) | 104.4 | 29.4 | 100.8 | 25.6 | 0.526 |
| Antihypertensive drugs n (%) | 18 | 42.9 | 28 | 59.6 | 0.118 |
| Lipidlowering drugs n (%) | 22 | 52.4 | 30 | 63.8 | 0.279 |
| Antidiabetic drugs n(%) | 37 | 88.1 | 44 | 93.6 | 0.369 |
Values are means [standard deviations (SD)] for normally distributed continuous data and medians (interquartile range) for asymmetrically distributed continuous data
BMI Body mass index, METs Metabolic equivalent, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, SD Standard Deviation, IQR Interquartile Range